Bioceres Crop Solutions (NASDAQ:BIOX) Posts Quarterly Earnings Results, Misses Expectations By $0.33 EPS

Bioceres Crop Solutions (NASDAQ:BIOX) released its quarterly earnings data on Tuesday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.33), reports. The firm had revenue of $55.90 million during the quarter, compared to analyst estimates of $79.00 million. Bioceres Crop Solutions had a negative return on equity of 33.17% and a negative net margin of 94.76%.

Here are the key takeaways from Bioceres Crop Solutions’ conference call:

• Fiscal 2026 revenue declined 18% to $238 million, while reported gross profit fell 21% to $82.9 million, reflecting the seed-business reconfiguration and weaker Crop Protection and inoculant sales.
• Fourth-quarter revenue was broadly stable year over year at $55.9 million, led by 36% growth in Crop Nutrition, while cost reductions helped adjusted EBITDA improve to positive $0.6 million from negative $9.6 million a year earlier.
• Management said the company is entering fiscal 2027 with a leaner cost structure and is targeting approximately 40% gross margins, supported by a simplified portfolio focused on higher-value products and core markets such as Brazil.
• Liquidity and capital structure remain significant risks, with $213.6 million of net financial debt and $118.6 million of secured notes classified as short term amid ongoing litigation over note acceleration and foreclosure.

Bioceres Crop Solutions Stock Performance

Shares of NASDAQ BIOX opened at $0.40 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.70 and a current ratio of 0.88. The firm has a market cap of $25.58 million, a price-to-earnings ratio of -0.11 and a beta of 0.44. The business’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.44. Bioceres Crop Solutions has a 52 week low of $0.30 and a 52 week high of $2.19.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Bioceres Crop Solutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bioceres Crop Solutions currently has a consensus rating of “Reduce” and an average target price of $2.00.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp. is an agricultural biotechnology company focused on developing, manufacturing and commercializing a range of crop inputs designed to enhance yields and improve sustainability. The company’s portfolio includes biological seed treatments, inoculants for nitrogen fixation, specialty fertilizers and proprietary biopesticides, which are formulated to support plant health and resilience under varying environmental conditions.

Among its flagship offerings is the HB4 drought-tolerant wheat technology, the first genetically modified wheat developed to withstand water stress, which has received regulatory approval in several markets.